TEST:

AVENIO Tumor Tissue CGP Kit

AMP/ASCO/CAP tiers were obtained with NMP for AVENIO or PierianDx for TSO. ESCAT inclusion was determined manually.

Two commercially available CGP solutions with tertiary analysis software had differences in the detection of TMB and ESCAT biomarkers, including CNAs. These differences can be largely explained by differences in variant calling and filtering algorithms and are important considerations for any diagnostic CGP offering, raising concern of inaccurate results if not properly controlled.

Conclusions CGP tests are being utilized in precision oncology, but NGS workflows and bioinformatics pipelines can be difficult to implement. The AVENIO CGP Tumor Tissue Kit is highly reproducible across sites and operators, achieving high sequencing quality metrics and diagnostic sensitivity.

We observed a high degree of agreement between the AVENIO Kit and F1CDx for all genomic variants and the genomic signatures TMB, MSI, and gLOH. Pres. at EFLM 2022

"Roche (SIX: RO, ROG;OTCQX: RHHBY) today announced that it will be showcasing next generation diagnostics solutions that will deliver fast and accurate results to help clinicians improve patient care and help reduce the healthcare burden at the 24th IFCC-EFLM European Congress of Clinical Chemistry and Laboratory Medicines (EuroMedLab) in Munich, Germany (rescheduled dates 10 - 14 April 2022)...An evaluation of the recently launched AVENIO Tumor Tissue Comprehensive Genomic Profiling (CGP) Kit for oncology research will be presented."

This new kit provides laboratories with distributed reagents and a cloud-based analysis software, for an end-to-end in-house solution to profile 324 genes associated with solid tumors across multiple cancer types, including genomic loss of heterozygosity, microsatellite instability, and tumor mutation burden. Here, we report high reproducibility and performance across five laboratory sites using a characterized panel of FFPET samples.